September 23, 2019
FDA: Class I recall of Allergan Natrelle Biocell textured breast implants
Editor's Note
The Food & Drug Administration (FDA) on September 12 designated the recall by Allergan of its Natrelle Biocell textured breast implants as Class I, the most serious.
The recall was initiated because of a six times higher rate of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a cancer of the immune system, which has been associated with these implants.
Distribution dates are September 14, 2014, to July 24, 2019.
Free Daily News
- Strategies for effective nurse-led change
- Review: How effective is initial virtual acute orthopedic care?
- Staffing: Improving patient flow with LPNs
- Enhanced PPE among updates to improve instrument sterilization safety
- First transatlantic robotic thrombectomy performed
- Joint Commission releases National Performance Goal briefs
- Review on pneumatic tourniquet safety
- Coronary computed tomography angiography helps predict first coronary events
- Environment influences OR team performance
- Ambulatory shift transforming care models for high-acuity patients
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement